Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT07280013
Recruiting
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Phase 1 · United States · 19 sites
Registry update: 30 Oct 2026
NCT07258511
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3 · Australia, Brazil, Canada, China, Germany, Spain, France, United Kingdom, Greece, Israel, Italy, Japan, Netherlands, Norway, United States · 156 sites
Registry update: 3 Nov 2026
NCT07410494
Recruiting
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/2 · China · 1 site
Registry update: 18 Feb 2026
NCT07236502
Recruiting
Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
Not applicable · United States · 2 sites
Registry update: 6 Oct 2026
NCT07377435
Recruiting
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Phase 1 · United States · 1 site
Registry update: 8 May 2026
NCT07564219
Recruiting
BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma
Not applicable · Germany · 1 site
Registry update: 4 May 2026
NCT07312942
Recruiting
Effects of Controlled Breathing Added to Therapeutic Exercise in Multiple Myeloma
Not applicable · Spain · 1 site
Registry update: 1 Oct 2026
NCT07579234
Recruiting
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
Phase 3 · China · 1 site
Registry update: 12 May 2026
NCT07547007
Recruiting
Benefits of a 6-month, Individualized, Hybrid, "Real-life" Adapted Physical Activity Program on the Quality of Life of Patients Treated for Multiple Myeloma
Not applicable · France · 2 sites
Registry update: 23 Apr 2026
NCT07096778
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Phase 2 · United Kingdom, United States · 31 sites
Registry update: 21 Sept 2026
NCT07225738
Recruiting
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
Not applicable · United States · 11 sites
Registry update: 20 Feb 2026
NCT07336823
Recruiting
JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma
Early phase 1 · China · 1 site
Registry update: 13 Jan 2026
NCT06980480
Recruiting
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Phase 3 · Austria, Australia, Brazil, Canada, Czechia, Germany, Denmark, Spain, United Kingdom, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Romania, United States · 76 sites
Registry update: 13 Oct 2026
NCT07322159
Recruiting
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
Early phase 1 · China · 1 site
Registry update: 9 Nov 2026
NCT07095452
Recruiting
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Phase 2/3 · Spain, France, Japan, Norway, United States · 50 sites
Registry update: 19 Oct 2026
Conflicting statuses (updated in the registry within the last month)
NCT07333430
Recruiting
Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
Phase 1 · Israel · 1 site
Registry update: 16 Oct 2026
NCT07094048
Recruiting
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Phase 4 · Canada · 2 sites
Registry update: 22 Jul 2026
NCT07222761
Recruiting
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 3 · Austria, Australia, Belgium, Brazil, Chile, Czechia, Germany, Spain, France, United Kingdom, Greece, Italy, South Korea, Netherlands, Poland, Taiwan, United States · 121 sites
Registry update: 4 Nov 2026
NCT07514052
Recruiting
Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study
Not applicable · China · 1 site
Registry update: 7 Apr 2026
NCT07297329
Recruiting
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Phase 3 · China · 1 site
Registry update: 29 Jan 2026

Ordered by registry start date. Freshness and sponsorship never change the order.